{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T09:34:35Z","timestamp":1763372075260,"version":"3.45.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,17]]},"DOI":"10.7759\/cureus.97037","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T09:29:13Z","timestamp":1763371753000},"source":"Crossref","is-referenced-by-count":0,"title":["Effect of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors in the Management of Hyponatremia Associated With Syndrome of Inappropriate Antidiuresis"],"prefix":"10.7759","author":[{"given":"Yasir","family":"Kammawal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaheer Ahmad","family":"Kammawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tajdar","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahzad","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiqar","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae162","article-title":"Hyponatraemia-treatment standard 2024","volume":"39","author":"Spasovski G","year":"2024","unstructured":"Spasovski G. Hyponatraemia-treatment standard 2024. Nephrol Dial Transplant. 2024, 39:1583-92. 10.1093\/ndt\/gfae162","journal-title":"Nephrol Dial Transplant"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnad010","article-title":"Syndrome of inappropriate antidiuresis: from pathophysiology to management","volume":"44","author":"Warren AM","year":"2023","unstructured":"Warren AM, Grossmann M, Christ-Crain M, Russell N. Syndrome of inappropriate antidiuresis: from pathophysiology to management. Endocr Rev. 2023, 44:819-61. 10.1210\/endrev\/bnad010","journal-title":"Endocr Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019090944","article-title":"A randomized trial of empagliflozin to increase plasma sodium levels in patients with the syndrome of inappropriate antidiuresis","volume":"31","author":"Refardt J","year":"2020","unstructured":"Refardt J, Imber C, Sailer CO, et al.. A randomized trial of empagliflozin to increase plasma sodium levels in patients with the syndrome of inappropriate antidiuresis. J Am Soc Nephrol. 2020, 31:615-24. 10.1681\/ASN.2019090944","journal-title":"J Am Soc Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2022050623","article-title":"Treatment effect of the SGLT2 inhibitor empagliflozin on chronic syndrome of inappropriate antidiuresis: results of a randomized, double-blind, placebo-controlled, crossover trial","volume":"34","author":"Refardt J","year":"2023","unstructured":"Refardt J, Imber C, Nobbenhuis R, et al.. Treatment effect of the SGLT2 inhibitor empagliflozin on chronic syndrome of inappropriate antidiuresis: results of a randomized, double-blind, placebo-controlled, crossover trial. J Am Soc Nephrol. 2023, 34:322-32. 10.1681\/ASN.2022050623","journal-title":"J Am Soc Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-024-02606-3","article-title":"Severe hyponatremia correction, mortality, and central pontine myelinolysis","volume":"2","author":"Seethapathy H","year":"2023","unstructured":"Seethapathy H, Zhao S, Ouyang T, et al.. Severe hyponatremia correction, mortality, and central pontine myelinolysis. NEJM Evid. 2023, 2:EVIDoa2300107. 10.1007\/s10157-024-02606-3","journal-title":"NEJM Evid"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu040","article-title":"Clinical practice guideline on diagnosis and treatment of hyponatraemia","volume":"29","author":"Spasovski G","year":"2014","unstructured":"Spasovski G, Vanholder R, Allolio B, et al.. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant. 2014, 29:i1-39. 10.1093\/ndt\/gfu040","journal-title":"Nephrol Dial Transplant"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.11176","article-title":"Diagnosis and management of hyponatremia: a review","volume":"328","author":"Adrogu\u00e9 HJ","year":"2022","unstructured":"Adrogu\u00e9 HJ, Tucker BM, Madias NE. Diagnosis and management of hyponatremia: a review. JAMA. 2022, 328:280-91. 10.1001\/jama.2022.11176","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-025-02388-5","article-title":"SGLT2 inhibitor requires co-administration with diuretics to effectively reduce interstitial fluid retention: the DAPA-BODY trial [PREPRINT]","volume":"0","author":"Masuda T","year":"2025","unstructured":"Masuda T, Asakura-Kinoshita M, Oka K, et al.. SGLT2 inhibitor requires co-administration with diuretics to effectively reduce interstitial fluid retention: the DAPA-BODY trial [PREPRINT]. Hypertens Res. 2025, 0:0. 10.1038\/s41440-025-02388-5","journal-title":"Hypertens Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab048.1263","article-title":"What does SGLT2 inhibition add in managing hyponatremia secondary to syndrome of inappropriate antidiuresis (SIAD)?","volume":"5","author":"Jalal FH","year":"2021","unstructured":"Jalal FH, Ibrahim L, Lim QH, et al.. What does SGLT2 inhibition add in managing hyponatremia secondary to syndrome of inappropriate antidiuresis (SIAD)?. J Endocr Soc. 2021, 5:A619-20. 10.1210\/jendso\/bvab048.1263","journal-title":"J Endocr Soc"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.15605\/jafes.040.S1.160","article-title":"The role of dapagliflozin as an adjunctive therapy in SIADH-induced hyponatremia","volume":"40","author":"Ahmad KB","year":"2025","unstructured":"Ahmad KB, Nandini N. The role of dapagliflozin as an adjunctive therapy in SIADH-induced hyponatremia. ASEAN Fed Endocr Soc. 2025, 40:94. 10.15605\/jafes.040.S1.160","journal-title":"ASEAN Fed Endocr Soc"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.02.028","article-title":"SGLT2 inhibition: neither a diuretic nor a natriuretic","volume":"83","author":"Packer M","year":"2024","unstructured":"Packer M. SGLT2 inhibition: neither a diuretic nor a natriuretic. J Am Coll Cardiol. 2024, 83:1399-402. 10.1016\/j.jacc.2024.02.028","journal-title":"J Am Coll Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes","volume":"148","author":"Packer M","year":"2023","unstructured":"Packer M, Wilcox CS, Testani JM. Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes. Annu Rev Physiol. 2023, 148:354-72. 10.1161\/CIRCULATIONAHA.123.064346","journal-title":"Annu Rev Physiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s42000-023-00430-0","article-title":"Long-term efficacy of empagliflozin as an add-on treatment for chronic SIAD: a case report and literature review","volume":"22","author":"Bioletto F","year":"2023","unstructured":"Bioletto F, Varaldo E, Prencipe N, Benso A, Berton AM. Long-term efficacy of empagliflozin as an add-on treatment for chronic SIAD: a case report and literature review. Hormones (Athens). 2023, 22:343-7. 10.1007\/s42000-023-00430-0","journal-title":"Hormones (Athens)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/1354750X.2021.1970808","article-title":"Can treatment response to SGLT2-inhibitors in syndrome of inappropriate antidiuresis be predicted by copeptin, natriuretic peptides and inflammatory markers?","volume":"26","author":"Nobbenhuis R","year":"2021","unstructured":"Nobbenhuis R, Refardt J, Vogt D, Sailer CO, Winzeler B, Christ-Crain M. Can treatment response to SGLT2-inhibitors in syndrome of inappropriate antidiuresis be predicted by copeptin, natriuretic peptides and inflammatory markers?. Biomarkers. 2021, 26:647-55. 10.1080\/1354750X.2021.1970808","journal-title":"Biomarkers"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.07.006","article-title":"Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations","volume":"126","author":"Verbalis JG","year":"2013","unstructured":"Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, Thompson CJ. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013, 126:S1-42. 10.1016\/j.amjmed.2013.07.006","journal-title":"Am J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp066837","article-title":"The syndrome of inappropriate antidiuresis","volume":"356","author":"Ellison DH","year":"2007","unstructured":"Ellison DH, Berl T. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007, 356:2064-72. 10.1056\/NEJMcp066837","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxab153","article-title":"A single-center cost analysis assessing a change in vasopressin formulation","volume":"78","author":"Kelly CE","year":"2021","unstructured":"Kelly CE, Miller C, Darko W, et al.. A single-center cost analysis assessing a change in vasopressin formulation. Am J Health Syst Pharm. 2021, 78:1238-43. 10.1093\/ajhp\/zxab153","journal-title":"Am J Health Syst Pharm"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073651","article-title":"An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors","volume":"23","author":"Salvatore T","year":"2022","unstructured":"Salvatore T, Galiero R, Caturano A, et al.. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci. 2022, 23:3651. 10.3390\/ijms23073651","journal-title":"Int J Mol Sci"},{"key":"ref19","article-title":"Mechanisms of SGLT2 inhibitors in cardiovascular and kidney disease","volume":"19","author":"Packer M","year":"2023","unstructured":"Packer M. Mechanisms of SGLT2 inhibitors in cardiovascular and kidney disease. Nat Rev Nephrol. 2023, 19:193-207.","journal-title":"Nat Rev Nephrol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI167700","article-title":"Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors","volume":"133","author":"Tuttle KR","year":"2023","unstructured":"Tuttle KR. Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors. J Clin Invest. 2023, 133:e167700. 10.1172\/JCI167700","journal-title":"J Clin Invest"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJV","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803760","article-title":"A copeptin-based approach in the diagnosis of diabetes insipidus","volume":"379","author":"Fenske W","year":"2018","unstructured":"Fenske W, Refardt J, Chifu I, et al.. A copeptin-based approach in the diagnosis of diabetes insipidus. N Engl J Med. 2018, 379:428-39. 10.1056\/NEJMoa1803760","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13243","article-title":"Evaluation of copeptin and commonly used laboratory parameters for the differential diagnosis of profound hyponatraemia in hospitalized patients: 'The Co-MED Study'","volume":"89","author":"Nigro N","year":"2017","unstructured":"Nigro N, Winzeler B, Suter-Widmer I, et al.. Evaluation of copeptin and commonly used laboratory parameters for the differential diagnosis of profound hyponatraemia in hospitalized patients: 'The Co-MED Study'. Clin Endocrinol (Oxf). 2017, 89:456-62. 10.1111\/cen.13243","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/427533-effect-of-sodium-glucose-co-transporter-2-sglt2-inhibitors-in-the-management-of-hyponatremia-associated-with-syndrome-of-inappropriate-antidiuresis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T09:29:13Z","timestamp":1763371753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/427533-effect-of-sodium-glucose-co-transporter-2-sglt2-inhibitors-in-the-management-of-hyponatremia-associated-with-syndrome-of-inappropriate-antidiuresis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.97037","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,11,17]]}}}